ArticleClinical epidemiology2017

Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia.

Katrina Wilcox Hagberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.